Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment.
Erjola Bidika, Hafsa Fayyaz, Marina Salib...
https://pubmed.ncbi.nlm.nih.gov/32968581Actively Recruiting
Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID07093606
Eltrombopag Induced Liver Dysfunction During Treatment of Immune Thrombocytopenic Purpura
Led by Sohag University · Updated on 2025-07-30
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the occurrence and severity of liver dysfunction in patients with immune thrombocytopenia (ITP) who receive the drug eltrombopag as part of their treatment. This study aims to better understand potential liver-related side effects in this patient group. The trial is interventional and sponsored by Sohag University. Participants with ITP will receive eltrombopag tablets. Throughout the study, liver function tests will be performed to monitor for any liver disorders. The primary outcome is to assess liver dysfunction incidence and severity between 3 to 6 months after starting eltrombopag. During the study, participants will have regular liver function tests to evaluate their liver health. Researchers will measure the liver function changes and document any liver-related adverse effects. The total participation period includes the treatment and follow-up for 3 to 6 months after starting eltrombopag, ensuring careful monitoring of liver status during this time.
CONDITIONS
Brief Title
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
Who Can Participate
Age: 18Years - 75Years
All Genders
Eligibility Criteria
You may qualify if you...
- Adult patients (≥18 years) diagnosed with primary ITP.
- Receiving eltrombopag as part of their treatment.
- Baseline liver function tests (LFTs) within normal limits.
- Patients with diabetes.
- Patients without diabetes.
- Patients with fatty liver.
- Patients without fatty liver
You will not qualify if you...
- Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD).
- Concurrent use of hepatotoxic drugs.
- Patients lost to follow-up.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 3 to 6 months
Participants receive Eltrombopag as part of their treatment for immune thrombocytopenic purpura (ITP).
Regular liver function tests during treatment to evaluate liver disorders.
Trial Site Locations
Total: 1 location
1
Sohag university hospital
Sohag, Egypt
Actively Recruiting
Loading map...
Research Team
P
Peter A Alfy, Resident
U
Usama M Abdelaal, Professor
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
New thrombopoietic growth factors.
David J Kuter
https://pubmed.ncbi.nlm.nih.gov/17289815Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
V V Ptushkin, O Yu Vinogradova, M M Pankrashkina...
https://pubmed.ncbi.nlm.nih.gov/30701925